Compare VIR & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | ERII |
|---|---|---|
| Founded | 2016 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 400.7M |
| IPO Year | 2019 | 2008 |
| Metric | VIR | ERII |
|---|---|---|
| Price | $10.72 | $6.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $19.43 | $17.07 |
| AVG Volume (30 Days) | ★ 1.9M | 929.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | 5.00 |
| EPS | ★ N/A | N/A |
| Revenue | $68,556,000.00 | ★ $134,987,000.00 |
| Revenue This Year | $270.22 | N/A |
| Revenue Next Year | N/A | $20.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.82 | $6.78 |
| 52 Week High | $11.94 | $18.31 |
| Indicator | VIR | ERII |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 30.97 |
| Support Level | $8.43 | N/A |
| Resistance Level | $11.80 | $11.58 |
| Average True Range (ATR) | 0.48 | 0.23 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 51.01 | 4.67 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.